Form 10-Q · Quarterly report
Linde plc 10-Q, filed Jul 31, 2026
- Filed
- CIK
- 0001707925
- Accession no.
- 0001628280-26-051289
Summary
Linde plc reported second-quarter 2026 sales of $9.289 billion, up 9% from the same period a year earlier, driven by volume, price, currency translation and acquisitions, with reported net income rising 9% and diluted earnings per share up 11%. Operating profit rose 8% on a reported basis to $2.554 billion and 7% on an adjusted basis, as productivity savings, higher pricing and currency gains offset cost inflation.
Key points
- Sales rose 9% to $9.289 billion in the quarter and 9% to $18.070 billion for the six months ended June 30, 2026.
- EBITDA was $3.553 billion in the quarter, up $224 million from $3.329 billion a year earlier; adjusted EBITDA was $3.572 billion.
- Adjusted diluted EPS rose $0.41, or 10%, in the quarter and $0.78, or 10%, for the six months, while reported diluted EPS rose 11% and 12% respectively.
- The reported effective tax rate was 24.0% for the quarter and 23.7% for the six months; headcount was 64,649, down 193 from June 30, 2025.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Results of operations Below is a discussion of the results of operations for the second quarter of 2026 and for the six months ended June 30, 2026 compared to the respective 2025 periods. Sales Quarter Ended June 30, 2026 vs. 2025 Six months ended June 30, 2026 vs. 2025 % Change % Change Factors Contributing to Changes - Sales Volume 2 % 2 % Price/Mix 2 % 2 % Cost pass-through 1 % 1 % Currency 2 % 3 % Acquisitions/divestitures 1 % 1 % Engineering 1 % — % 9 % 9 % Sales increased by 9% both in the second quarter of 2026 and for the six months ended June 30, 2026, versus the respective 2025 periods. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.